Innate Pharma SA: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Apr 30, 2025 and accepted by EDGAR at Apr 30, 2025, 09:01 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | EUR 20.1m | ifrs-full:Revenue |
| Operating income | 12 months2024-01-01 to 2024-12-31 | −EUR 51.6m | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2024-01-01 to 2024-12-31 | EUR 0 | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2024-01-01 to 2024-12-31 | −EUR 49.5m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | −EUR 0.61 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | −EUR 0.61 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | −EUR 6.9m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | EUR 391.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2024-12-31 | EUR 66.4m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2024-12-31 | EUR 85.7m | ifrs-full:CurrentAssets |
| Total assets | At period end2024-12-31 | EUR 111.1m | ifrs-full:Assets |
| Current liabilities | At period end2024-12-31 | EUR 33.0m | ifrs-full:CurrentLiabilities |
| Shareholders' equity | At period end2024-12-31 | EUR 8.8m | ifrs-full:Equity |
| Shares outstanding | At period end2024-12-31 | 83,830,336 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001598599-25-000042. Last ingested by Listed: Nov 12, 2026, 17:11 ET. Listed shows no prices and gives no investment advice.